Clinical trials: DME
Diabetic Macular Edema (DME)
Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.
The goal of this clinical trial is to learn if the efficacy of dexamethasone implant combined with anti-VEGF superior to anti-VEGF monotherapy in the treatment of DME in Chinese patients.
- Trial name
- NCT06846073
- Testing
- The combination of intravitreal anti-VEGF and dexamethasone implants injections.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Diabetic Macular Edema
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
- Trial name
- NCT02348918
- Testing
- Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg
- Where
- 17 sites in United States
- Volunteers
- 218 people
- Sponsor
- Allegro Ophthalmics, LLC
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Observation of Treatment Patterns With Lucentis in Approved Indications
A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema…
- Trial name
- OCEAN (NCT02194803)
- Where
- Germany
- Volunteers
- 5,778 people
- Sponsor
- Novartis Pharmaceuticals
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetic Macular Edema
The Effect of Intravitreal Ozurdex on DME After Cataract Surgery
The purpose of this study is to assess the efficacy and safety of OZURDEX (dexamethasone intravitreal implant) 0.7 mg administered immediately after phacoemulsification and intraocular lens implantation in type 1 or 2 diabetic…
- Trial name
- NCT01748487
- Testing
- dexamethasone intravitreal implant (OZURDEX)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University Health Network, Toronto
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Diabetic Macular Edema
DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME).
- Trial name
- DA VINCI (NCT00789477)
- Testing
- Laser Photocoagulation, Intravitreal Aflibercept Injection
- Where
- 47 sites in United States, Austria and 1 more
- Volunteers
- 221 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
3 Month Outcome of Ziv-aflibercept for DME
The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with intravitreal ziv-aflibercept.
- Trial name
- NCT02772497
- Testing
- Ziv aflibercept
- Volunteers
- 10 people
- Sponsor
- Marashi Eye Clinic
Proliferative Diabetic Retinopathy (PDR)
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
- Trial name
- HERO (NCT07118670)
- Testing
- Aflibercept 8mg
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Edward Wood, MD
Macular Edema
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
- Trial name
- NCT02188173
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Allergan
Diabetic Macular Edema
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
- Trial name
- ELAAVATE (NCT06942520)
- Testing
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sierra Eye Associates
Diabetic Macular Edema
Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A
The goal of this clinical trial is to to evaluate the changes in retinal microvasculature secondary to intra-ocular pressure changes post intra-vitreal injection in patients with diabetic macular oedema highlighting the effect of…
- Trial name
- NCT05861466
- Testing
- intra-vitreal injection of Ranibizumab, anterior chamber paracentesis
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams University
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian
Diabetic Retinopathy, Macular Edema
Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)
This study is designed to report 3-year result of triple therapy of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation for intractable diabetic macular edema.
- Trial name
- NCT01202461
- Testing
- Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Samsung Medical Center
Diabetic Macular Edema, Cataract
Cataract DME - Peri vs. Intraop
Goals of the study are to evaluate how peri-operative versus intra-operative anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with persistent diabetic macular edema who are undergoing cataract surgery…
- Trial name
- NCT03920878
- Testing
- Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
- Where
- 2 sites in United States
- Sponsor
- Emory University
Clinically Significant Macular Edema Due to Diabetes Mellitus
Anti-VEGF Therapy Versus Dexamethasone Implant for DME
We look at a randomized comparative study of 2 FDA approved anti-VEGF agents(aflibercept and ranibizumab) and see how they compare against the dexamethasone implant for phakic as well as pseudophakic eyes with treatment naive…
- Trial name
- NCT03999125
- Testing
- Aflibercept,, Ranibizumab Injection, Ozurdex Drug Implant Product
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Sudhalkar Eye Hospital
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and…
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT03499223
- Testing
- Ranibizumab 0.5mg, THR-317 8mg
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Oxurion